secwatch / observer

8-K filed April 20, 2026, 7:59 PM ET ticker NKTR CIK 0000906709

other material confidence high sentiment positive materiality 0.70

Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049

NEKTAR THERAPEUTICS

SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.
SALT≤30 at wk52: 30.2% low, 35.0% high vs 8.4% placebo (p=0.023). SALT50: 37.7% low, 38.8% high vs 13.6% placebo.
94% of 31 patients completed 16-week extension; no discontinuations due to TEAEs. Injection site reactions mild-to-moderate, self-resolving within 5 days.
Nektar will submit results to a medical conference in 2026 and plans to advance rezpegaldesleukin into registrational trials in alopecia areata.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-162763
form_type: 8-K
ticker: NKTR
cik: 0000906709
company_name: NEKTAR THERAPEUTICS
filed_at: 2026-04-20T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.914358+00:00
generated_at: 2026-05-15T05:26:00.099388+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-162763
json_url: https://secwatch.observer/filing/0001193125-26-162763.json
markdown_url: https://secwatch.observer/filing/0001193125-26-162763.md
text_url: https://secwatch.observer/filing/0001193125-26-162763.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526162763/0001193125-26-162763-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/906709/000119312526162763/d25375d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MVIS

MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026

MICROVISION, INC. June 1, 2026, 5:02 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIB

Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline

BlockchAIn Digital Infrastructure, Inc. June 1, 2026, 4:57 PM ET other_material Items 1.01, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-162763

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.